Sanofi’s quadrivalent flu vaccine approved by US FDA

News

The FDA has approved Sanofi Pasteur's supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent.

Sanofi Pasteur is the vaccines division of Sanofi. Like the division's Fluzone vaccine, which is administered to over 50 million people in the US each year, Fluzone Quadrivalent is licensed for use in children six months of age and older, adolescents and adults.

Fluzone Quadrivalent includes two A strains and two B strains to help protect against influenza disease. It will be available in the US in time for the 2013 influenza season.

"Sanofi Pasteur is committed to providing new immunization options for the prevention of influenza to help healthcare providers meet the specific immunization needs of all types of patients, and we are excited to introduce Fluzone Quadrivalent vaccine as an important new addition to our Fluzone family of specialized influenza vaccines.
"Protection against the type B flu strain may be an especially important factor that healthcare providers consider when immunizing children since influenza B causes a substantial number of illnesses, hospitalizations and deaths in the pediatric population."

David Greenberg, MD, Vice President U.S. Scientific and Medical Affairs, Sanofi Pasteur.

Sanofi's 4-in-1 influenza vaccine joins GlaxoSmithKline's Fluarix Quadrivalent and AstraZeneca's MedImmune FluMist Quadrivalent that are already approved for use in the United States.

 

 

Related news:

FDA approves Sanofi Pasteur influenza vaccine (Reuters)

Reference links:

Sanofi press release

profile mask

HannahBlake


Sales & Marketing
Launch Excellence: Moments of Truth
Sponsored

Launch Excellence: Moments of Truth

The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns, creating challenges and opportunities.

Patients
Patient Recruitment for Rare Disease Trials Summit banner image
Partner Content

Patient Recruitment for Rare Disease Trials Summit

Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical dispersion, low awareness, and limited eligible patient pools.